These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Safety biomarkers in preclinical development: translational potential. Sasseville VG; Mansfield KG; Brees DJ Vet Pathol; 2014 Jan; 51(1):281-91. PubMed ID: 24091814 [TBL] [Abstract][Full Text] [Related]
5. Mass spectrometry-based biomarkers in drug development. Miller RA; Spellman DS Adv Exp Med Biol; 2014; 806():341-59. PubMed ID: 24952191 [TBL] [Abstract][Full Text] [Related]
6. Drug discovery in advanced prostate cancer: translating biology into therapy. Yap TA; Smith AD; Ferraldeschi R; Al-Lazikani B; Workman P; de Bono JS Nat Rev Drug Discov; 2016 Oct; 15(10):699-718. PubMed ID: 27444228 [TBL] [Abstract][Full Text] [Related]
7. Validating therapeutic targets through human genetics. Plenge RM; Scolnick EM; Altshuler D Nat Rev Drug Discov; 2013 Aug; 12(8):581-94. PubMed ID: 23868113 [TBL] [Abstract][Full Text] [Related]
8. Scientific diligence for oncology drugs: a pharmacology, translational medicine and clinical perspective. Parasrampuria DA; Bandekar R; Puchalski TA Drug Discov Today; 2020 Oct; 25(10):1855-1864. PubMed ID: 32693162 [TBL] [Abstract][Full Text] [Related]
9. Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation. Alymani NA; Smith MD; Williams DJ; Petty RD Eur J Cancer; 2010 Mar; 46(5):869-79. PubMed ID: 20138504 [TBL] [Abstract][Full Text] [Related]
10. Biomarkers for the development of new medications for cocaine dependence. Bough KJ; Amur S; Lao G; Hemby SE; Tannu NS; Kampman KM; Schmitz JM; Martinez D; Merchant KM; Green C; Sharma J; Dougherty AH; Moeller FG Neuropsychopharmacology; 2014 Jan; 39(1):202-19. PubMed ID: 23979119 [TBL] [Abstract][Full Text] [Related]
11. Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? Carden CP; Sarker D; Postel-Vinay S; Yap TA; Attard G; Banerji U; Garrett MD; Thomas GV; Workman P; Kaye SB; de Bono JS Drug Discov Today; 2010 Feb; 15(3-4):88-97. PubMed ID: 19961955 [TBL] [Abstract][Full Text] [Related]
12. Chemical genetics-based target identification in drug discovery. Cong F; Cheung AK; Huang SM Annu Rev Pharmacol Toxicol; 2012; 52():57-78. PubMed ID: 21819237 [TBL] [Abstract][Full Text] [Related]
14. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety. Roses AD Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406 [TBL] [Abstract][Full Text] [Related]
15. The biomarker is not the end. Nohaile M Drug Discov Today; 2011 Oct; 16(19-20):878-83. PubMed ID: 21888986 [TBL] [Abstract][Full Text] [Related]
16. Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot. Hampel H; Lista S; Khachaturian ZS Alzheimers Dement; 2012 Jul; 8(4):312-36. PubMed ID: 22748938 [TBL] [Abstract][Full Text] [Related]
17. Challenges of biomarkers in drug discovery and development. Goodsaid F Expert Opin Drug Discov; 2012 Jun; 7(6):457-61. PubMed ID: 22471322 [TBL] [Abstract][Full Text] [Related]
18. [Translational approach for pharmacogenomics and personalized medicine]. Zhang W; Zhou HH Yao Xue Xue Bao; 2011 Jan; 46(1):1-5. PubMed ID: 21465801 [TBL] [Abstract][Full Text] [Related]
19. Teaching Targeted Drug Discovery and Development to Healthcare Professionals. Fruchter R; Ahmad M; Pillinger M; Galeano C; Cronstein BN; Gold-von Simson G Clin Transl Sci; 2018 May; 11(3):277-282. PubMed ID: 29110398 [No Abstract] [Full Text] [Related]